Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors

Journal of Nuclear Medicine

Volumn 49, Issue 11, 2008, Pages 1804-1808

  Nahmias, Claude ^a   Wahl, Lindi M ^b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

18F FDG; Cancer; Reproducibility; SUV

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; ESOPHAGUS CANCER; FEMALE; GLUCOSE BLOOD LEVEL; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALE; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCIBILITY; THYROID CANCER;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 57349145902     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.054239     Document Type: Article

References (20)

1. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496-507.
2. Weber WA. Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med. 2005;46:983-995.
3. Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease. J Nucl Med. 2002;43:1018-1027.
4. 18F-FDG PET. J Nucl Med. 2005;46:1144-1150.
5. Avril N, Sassen S, Schmalfeldt B, et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J Clin Oncol. 2005;23:7445-7453.
6. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol. 2003;21:4604-4610.
7. 18F-FDG PET/CT. J Nucl Med. 2007;48:744-751.
8. Kelloff GJ, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005;11:2785-2808.
9. 18F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784-788.
10. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D- glucose uptake at PET. Radiology. 1995;196:167-173.
11. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med. 1999;40:1771-1777.
12. Krak N, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294-301.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;8476:307-310.
14. Press WH, Teukolsky SA, Vetterling WT, Flannery BP. Numerical Recipes in C: The Art of Scientific Computing. 2nd ed. Cambridge, U.K.: Cambridge University Press; 1992:620-628.
15. 18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med. 2000;27:731-743.
16. 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999;26:22-30.
17. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med. 1999;26:1345-1348.
18. 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med. 2006;47:1440-1446.
19. Huang SC. Anatomy of SUV. Nucl Med Biol. 2000;27:643-646.
20. Chen ET, Nichols JH, Duh SH, Hortin G. Performance evaluation of blood glucose monitoring devices. Diabetes Technol Ther. 2003;5:749-768.